Listed drug maker AFT Pharmaceuticals said it was sticking with the development of its drug Pascomer despite a disappointing study result and the withdrawal of its US licencee.
The clinical study of the use of Pascomer as a topical treatment for facial angiofibromas (FAs), which often develop from
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
